BR112016010106A2 - ensaios para igfbp7 com melhor desempenho em amostras biológicas - Google Patents
ensaios para igfbp7 com melhor desempenho em amostras biológicasInfo
- Publication number
- BR112016010106A2 BR112016010106A2 BR112016010106A BR112016010106A BR112016010106A2 BR 112016010106 A2 BR112016010106 A2 BR 112016010106A2 BR 112016010106 A BR112016010106 A BR 112016010106A BR 112016010106 A BR112016010106 A BR 112016010106A BR 112016010106 A2 BR112016010106 A2 BR 112016010106A2
- Authority
- BR
- Brazil
- Prior art keywords
- igfbp7
- assays
- biological samples
- best performing
- immunoassays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900942P | 2013-11-06 | 2013-11-06 | |
| US201462054324P | 2014-09-23 | 2014-09-23 | |
| US201462064380P | 2014-10-15 | 2014-10-15 | |
| PCT/US2014/064327 WO2015069880A1 (en) | 2013-11-06 | 2014-11-06 | Assays for igfbp7 having improved performance in biological samples |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016010106A2 true BR112016010106A2 (pt) | 2017-12-05 |
Family
ID=53042071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016010106A BR112016010106A2 (pt) | 2013-11-06 | 2014-11-06 | ensaios para igfbp7 com melhor desempenho em amostras biológicas |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9822172B2 (https=) |
| EP (2) | EP3066221A4 (https=) |
| JP (4) | JP2017501211A (https=) |
| KR (1) | KR102404285B1 (https=) |
| CN (1) | CN105793439B (https=) |
| AU (1) | AU2014346695B2 (https=) |
| BR (1) | BR112016010106A2 (https=) |
| CA (2) | CA2929547C (https=) |
| EA (1) | EA201690731A1 (https=) |
| HK (1) | HK1221490A1 (https=) |
| MX (1) | MX375701B (https=) |
| WO (1) | WO2015069880A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2836218T3 (es) | 2008-10-21 | 2021-06-24 | Astute Medical Inc | Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| WO2011075744A1 (en) | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP3361255B1 (en) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN107110871B (zh) * | 2014-10-29 | 2019-09-27 | 豪夫迈·罗氏有限公司 | 用于死亡的风险预测的生物标志物 |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN108139409B (zh) * | 2015-10-08 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 当在外科手术之前测量时用于预测aki的风险的igfbp7 |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN110709103B (zh) | 2017-04-05 | 2024-02-02 | 机敏医药股份有限公司 | 用于生物学样品中具有改善的性能的timp2的测定法 |
| KR20210019459A (ko) | 2018-05-24 | 2021-02-22 | 레니버스 테라퓨틱스, 인크. | 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법 |
| WO2020234482A1 (en) * | 2019-05-21 | 2020-11-26 | Universität Zürich | MAPKi RESISTANCE SIGNATURES |
| KR102533791B1 (ko) * | 2022-09-15 | 2023-05-18 | 경북대학교 산학협력단 | 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법 |
| EP4729541A1 (en) * | 2024-10-16 | 2026-04-22 | Paolo Fiorina | Anti- igfbp7 antibodies and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3029579C2 (de) | 1980-08-05 | 1985-12-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| US5166051A (en) | 1990-08-08 | 1992-11-24 | Genesis Labs, Inc. | Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6391265B1 (en) | 1996-08-26 | 2002-05-21 | Biosite Diagnostics, Inc. | Devices incorporating filters for filtering fluid samples |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6045899A (en) | 1996-12-12 | 2000-04-04 | Usf Filtration & Separations Group, Inc. | Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US7109030B2 (en) * | 2000-03-31 | 2006-09-19 | Nuvelo, Inc. | Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| US20020132983A1 (en) * | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| US20060263907A1 (en) | 2005-04-29 | 2006-11-23 | Zweig Stephen E | Fluorescence lateral flow immunoassay |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| JP2010517023A (ja) * | 2007-01-25 | 2010-05-20 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるｉｇｆｂｐ−７の使用 |
| WO2010043037A1 (en) * | 2008-10-14 | 2010-04-22 | National Research Council Canada | Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| EP2424566A4 (en) | 2009-05-01 | 2013-07-31 | Abbvie Inc | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
| WO2011075744A1 (en) | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011213684B2 (en) | 2010-02-05 | 2014-11-20 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2809369A1 (en) * | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
| BR112014010532A2 (pt) * | 2011-11-03 | 2017-04-18 | Tolera Therapeutics Inc | anticorpo e métodos para inibição seletiva de respostas de célula-t |
-
2014
- 2014-11-06 JP JP2016552481A patent/JP2017501211A/ja active Pending
- 2014-11-06 BR BR112016010106A patent/BR112016010106A2/pt not_active Application Discontinuation
- 2014-11-06 HK HK16109610.3A patent/HK1221490A1/zh unknown
- 2014-11-06 AU AU2014346695A patent/AU2014346695B2/en active Active
- 2014-11-06 CA CA2929547A patent/CA2929547C/en active Active
- 2014-11-06 CA CA3185700A patent/CA3185700A1/en active Pending
- 2014-11-06 CN CN201480066318.8A patent/CN105793439B/zh active Active
- 2014-11-06 EP EP14860878.9A patent/EP3066221A4/en not_active Withdrawn
- 2014-11-06 MX MX2016005834A patent/MX375701B/es active IP Right Grant
- 2014-11-06 WO PCT/US2014/064327 patent/WO2015069880A1/en not_active Ceased
- 2014-11-06 KR KR1020167014700A patent/KR102404285B1/ko active Active
- 2014-11-06 EP EP19158290.7A patent/EP3556863B1/en active Active
- 2014-11-06 US US15/035,205 patent/US9822172B2/en active Active
- 2014-11-06 EA EA201690731A patent/EA201690731A1/ru unknown
-
2017
- 2017-11-20 US US15/818,669 patent/US10562961B2/en active Active
-
2019
- 2019-11-25 JP JP2019212462A patent/JP2020048569A/ja active Pending
-
2020
- 2020-01-17 US US16/745,781 patent/US20200247879A1/en not_active Abandoned
-
2022
- 2022-01-13 JP JP2022003920A patent/JP7277623B2/ja active Active
-
2023
- 2023-01-06 JP JP2023000938A patent/JP2023052239A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016005834A (es) | 2016-11-17 |
| JP7277623B2 (ja) | 2023-05-19 |
| KR20160068988A (ko) | 2016-06-15 |
| US10562961B2 (en) | 2020-02-18 |
| US9822172B2 (en) | 2017-11-21 |
| CA2929547C (en) | 2023-02-28 |
| WO2015069880A1 (en) | 2015-05-14 |
| EP3066221A1 (en) | 2016-09-14 |
| CN105793439B (zh) | 2020-09-04 |
| JP2023052239A (ja) | 2023-04-11 |
| MX375701B (es) | 2025-03-06 |
| US20160289308A1 (en) | 2016-10-06 |
| AU2014346695B2 (en) | 2020-10-15 |
| EA201690731A1 (ru) | 2016-10-31 |
| EP3066221A4 (en) | 2017-09-20 |
| US20200247879A1 (en) | 2020-08-06 |
| JP2017501211A (ja) | 2017-01-12 |
| CA2929547A1 (en) | 2015-05-14 |
| CA3185700A1 (en) | 2015-05-14 |
| JP2020048569A (ja) | 2020-04-02 |
| JP2022068143A (ja) | 2022-05-09 |
| AU2014346695A1 (en) | 2016-06-16 |
| HK1221490A1 (zh) | 2017-06-02 |
| CN105793439A (zh) | 2016-07-20 |
| EP3556863B1 (en) | 2024-09-18 |
| EP3556863A1 (en) | 2019-10-23 |
| US20180066045A1 (en) | 2018-03-08 |
| KR102404285B1 (ko) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016010106A2 (pt) | ensaios para igfbp7 com melhor desempenho em amostras biológicas | |
| BR112016002685A2 (pt) | ensaios para timp2 que apresentam melhor desempenho em amostras biológicas | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| CO2017002710A2 (es) | Sistemas y métodos para la integración de la recolección de microfluido lagrimal y el análisis por flujo lateral de analitos de interés | |
| BR112014025384A8 (pt) | método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares | |
| MX377956B (es) | Sistemas y métodos para maximización de uso de muestras. | |
| BR112015026242A2 (pt) | dispositivo de coleta de fluido biológico e sistema de separação e testagem de fluido biológico | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| BR112015023239A2 (pt) | ensaio de combinação antígeno-anticorpo e métodos e composições para uso do mesmo | |
| BRPI0915086B8 (pt) | detecção do uso de canabis | |
| BR112014006432A2 (pt) | biomarcadores do câncer de pulmão e seus usos | |
| MX2013001042A (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
| MX2016013255A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
| CL2013000813A1 (es) | Dispositivo inmunocromatográfico que comprende una membrana que tiene un anticuerpo capaz de unirse a una proteina z-aat presente en una muestra de un portador del gen piz; metodo para determinar un portador del gen piz; metodo para diagnosticar una afección o enfermedad asociada con la deficiencia de aat; kits de inmunocromatografia | |
| MX2020003523A (es) | Deteccion de dimetilarginina simetrica. | |
| EA201400873A1 (ru) | Механическая промывка и измерительный прибор для выполнения анализов | |
| PE20160657A1 (es) | Composiciones y metodos para identificar un riesgo de cancer en un sujeto | |
| BR112013024686B8 (pt) | Ensaio de psa, e, reagente de ensaio de psa | |
| BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico | |
| AR105379A1 (es) | Dispositivo para detectar proteínas mal plegadas y sus métodos de uso | |
| MX2019000591A (es) | Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma. | |
| BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| BR112017017719A2 (pt) | imunoensaio homogêneo com compensação para sinal antecedente | |
| WO2014151290A3 (en) | Assay for predictive biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |